Cardival Medical

Santa Clara, United States Founded: 2002 • Age: 24 yrs Acquired By Haemonetics
A device for vascular access management is developed.

About Cardival Medical

Cardival Medical is a Healthcare company based in Santa Clara (United States) founded in 2002, and was acquired by Haemonetics in January 2021. A device for vascular access management is developed. Cardival Medical has raised $169.45 million across 13 funding rounds from investors including Haemonetics, GE Capital and WI Harper Group. The company has 158 employees. Cardival Medical offers products and services including Cell Saver, TEG 6s, and VASCADE. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its legal entity is CARDIVA MEDICAL, INC. Its competitors include Saranas, Aziyo Biologics and Cordis; 2 of its 3 listed competitors have raised funding.

Company details

Cardival Medical was founded in 2002 in Santa Clara, United States, where medical devices for vascular access are developed. Operations center on two products: Vascade, an extravascular bioabsorbable femoral access closure system, and CATALYST, used for temporary hemostasis and coagulation support in patients. The focus remains on vascular sector innovations, with activities based in the United States.

Key Metrics
  • Total Equity Funding
    $169.45M (USD)

    in 13 rounds

  • Latest Funding Round
    $45M (USD), Series E

    Jul 2020

  • Investors
  • Employee Count
    158
  • Acquired by
    Haemonetics

    (Jan 2021)

Products & Services of Cardival Medical

Cardival Medical offers a comprehensive portfolio of products and services, including Cell Saver, TEG 6s, and VASCADE.

Cell Saver
Cell Salvage

Device for recovering blood during surgical procedures

TEG 6s
Haemostasis Management

System for monitoring and analyzing blood clotting functions

VASCADE
Vascular Closure

Tool for sealing vascular access sites post-procedure

Funding Insights of Cardival Medical

Cardival Medical has successfully raised a total of $169.45M across 13 strategic funding rounds. The most recent funding activity was a Series E round of $45 million completed in July 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $169.45M
  • Total Rounds 13
  • Last Round Series E β€” $45M
  • First Round $10.5M

    (Nov 2003)

  • Investors Count 9

Latest 10 of 13 funding rounds of Cardival Medical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2020$45MSeries E––
–
Feb 2018Series D––
Feb 2018Debt – Conventional––
Jan 2018$39.24MSeries D–LKCM
Aug 2014$16.5MSeries D––
Aug 2014$12.5MDebt – Conventional––
Jul 2013$3.5MSeries D––
–
Mar 2013$16.93MSeries D––
Aug 2012Series D––
–
May 2008$15.5MSeries D––
Valuation history

10 investors in total: 10 institutional.

Investors in Cardival Medical

Cardival Medical has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Haemonetics, GE Capital and WI Harper Group.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Life Sciences focused VC firm investing in expansion & late stage start-ups in the US
2003ptvhc.comAustin, United States
canepahealthcare.com
Investment management services are provided by Luther King Capital Management.
1979lkcm.comFort Worth, United States
amkeyvc.com
PE firm investing in the US
galen.comStamford, United States
sycaventures.com
harbingervc.com
VC firm that does investment in early stage companies in the US & China
1993wiharper.comSan Francisco, United States
Commercial aircraft and equipment leasing and lending services are provided.
1932gecapital.comUnited States
Hematology products and solutions are provided for medical applications.
1971haemonetics.comBraintree, United States
Premium access

Investor details for Cardival Medical

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of Cardival Medical

4 dated milestones of Cardival Medical across 19 years, from founding to its latest funding, stage changes and deals.

  1. Founded Cardival Medical is founded.
  2. Funding First funding round of $10.5M.
  3. Funding Latest funding round, Series E, of $45.0M.
  4. Exit Acquired by Haemonetics.

Competitors of Cardival Medical

Cardival Medical has 3 listed competitors in our database, 2 of them funded. They include Saranas, Aziyo Biologics and Cordis.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
saranas.com2011Houston, United States$29.46M
A device is developed for detecting internal bleeding during catheterization.
aziyo.com2015Silver Spring, United States$49.59M162
Regenerative medicine products are developed for orthopedic and cardiovascular applications.
cordis.com1957Fremont, United States5
Cardiovascular and endovascular devices are developed and marketed by Cordis.
Premium access

Detailed competitors of Cardival Medical

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Cardiac and Vascular Disorders

3 companies that operate in the same segment as Cardival Medical (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Gene-editing therapies for coronary artery disease are developed.
2018Cambridge, Massachusetts, United StatesUSD 215.5 M255
Cardiac monitoring devices and applications are provided for heart health.
2010Mountain View, California, United StatesUSD 114.38 MUSD 6.18 M67
Therapies for lowering low-density lipoprotein cholesterol levels are developed.
1998Ann Arbor, Michigan, United StatesUSD 129.7 MUSD 332.31 M304
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Cardival Medical

Premium access

Complete news archive for Cardival Medical

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Cardival Medical

Cardival Medical was founded in 2002 and raised its 1st funding round 1 year after it was founded.

Cardival Medical is headquartered in Santa Clara, United States. It is registered at Santa Clara, California, United States.

Cardival Medical is a funded company, having raised a total of $169.45M across 13 funding rounds to date. The company's 1st funding round was a Series D of $15.5M, raised on Nov 2003.

Cardival Medical has 158 employees.

Cardival Medical was founded in 2002 in Santa Clara, United States, where medical devices for vascular access are developed. Operations center on two products: Vascade, an extravascular bioabsorbable femoral access closure system, and CATALYST, used for temporary hemostasis and coagulation support in patients. The focus remains on vascular sector innovations, with activities based in the United States.

Cardival Medical's top competitors include Aziyo Biologics, Cordis and Saranas.

Cardival Medical offers Cell Saver, TEG 6s, and VASCADE.

Cardival Medical has 10 investors. Key investors include Haemonetics, GE Capital, WI Harper Group, PTV Healthcare Capital, and Canepa Healthcare.

Cardival Medical operates through Cardiva Medical, Inc..

Yes. Cardival Medical was acquired by Haemonetics in January 2021.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available